INTENDED USE & DESCRIPTION

For use as quantitative controls for the determination of cytokine concentrations in biological fluids. Concentrations have been assigned using R&D Systems’ Quantikine® kits. Controls are prepared in diluted porcine serum with preservatives. They contain recombinant human cytokines at low, medium and high concentrations. Controls are supplied lyophilized.

STORAGE & STABILITY

Unreconstituted Controls should be stored at 2-8 °C and are stable for at least 6 months from date of receipt. Depending on the analyte of interest, reconstituted controls may be stable when stored at < -20 °C. Users should evaluate the frozen stability of the controls in their application or discard after use.

REAGENT PREPARATION

Reconstitute each vial with the volume of deionized or distilled water indicated on the product datasheet.

PROCEDURE & EXPECTED VALUES

Controls should be assayed in the same manner as unknown specimens.

The acceptable ranges for the analytes in these controls are printed on the product datasheet. Due to possible variations in techniques and methodologies, it is recommended that each laboratory determine its own target range. Laboratories using other test systems should establish their own acceptable ranges as these assays may produce different values.

TECHNICAL HINTS & LIMITATIONS OF THE PROCEDURE 

• The ranges were determined using R&D Systems’ Quantikine kits. If expected values are not obtained, verify that the lot numbers on the vials correspond with the lot numbers listed above and the correct volume of deionized or distilled water was used for reconstitution of the controls. 

• The results obtained with these controls depend upon several factors associated with methods and instrumentation. Test systems other than those supplied by R&D Systems may result in values that differ from those printed on this product datasheet.

Preparation and Storage

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: IGFBP-1

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. ALS (Acid Labile Subunit) is a liver-derived protein that exists in a ternary complex with Insulin-like Growth Factor (IGF)-binding Protein-3 (IGFBP-3) or IGFBP-5, and either IGF-I or IGF-II. ALS increases the half-life of IGF/IGFBP complexes in circulation.

• Long Name:

  Insulin-like Growth Factor Binding Protein 1

• Entrez Gene IDs:

  3484 (Human); 16006 (Mouse)

• Alternate Names:

  alpha-pregnancy-associated endometrial globulin; amniotic fluid binding protein; binding protein-25; binding protein-26; binding protein-28; growth hormone independent-binding protein; hIGFBP-1; IBP1; IBP-1; IGF-binding protein 1; IGFBP1; IGFBP-1; IGF-BP25; insulin-like growth factor binding protein 1; insulin-like growth factor-binding protein 1; Placental protein 12; PP12AFBP